5
Participants
Start Date
January 31, 2010
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Imatinib mesylate
400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Imatinib mesylate
600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Imatinib mesylate
400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
University of Pittsburgh Cancer Institute, Pittsburgh
Fox Chase Cancer Center, Philadelphia
Washington Cancer Institute, Washington D.C.
Duke University Medical Center, Durham
Carolinas Hematology Oncology Associates, Charlotte
Indiana University Cancer Center, Indianapolis
University of Iowa, Iowa City
Northwestern University, Chicago
MD Anderson Cancer Center, Houston
Cedars-Sinai Outpatient Cancer Center, Los Angeles
Sarcoma Oncology Center, Santa Monica
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Sarcoma Alliance for Research through Collaboration
OTHER